Adam C. Kinsey
Nessuna posizione attualmente
Profilo
Adam C.
Kinsey worked as a Director of Clinical Sciences & Operations at Genzyme Corp.
and as a Senior Director of Clinical Development at Aravas, Inc.
Precedenti posizioni note di Adam C. Kinsey
| Società | Posizione | Fine |
|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Direttore Tecnico/Scientifico/R&S | - |
Aravas, Inc.
 Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Direttore Tecnico/Scientifico/R&S | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Aravas, Inc.
Aravas, Inc. Pharmaceuticals: MajorHealth Technology Aravas, Inc. develops innovative drugs for the treatment of serious and life-threatening conditions. It develops dry powder formulations for various therapeutic molecules, including antibiotics, corticosteroids, nucleic acids, and insoluble and soluble molecules. The firm’s products include AeroVanc, an inhaled dry powder form of vancomycin in a capsule-based inhaler to treat methicillin-resistant staphylococcus aureus infections in patients with cystic fibrosis or other lung-compromising conditions; and AeroCort, a high performance inhaled corticosteroid product for the treatment of asthma in children. The company was founded by Cory Berkland, Chris Marich, Robert N. Neville, Taneli Jouhikainen, Chal Lenge and George Laurence in March 2007 and is headquartered in Austin, TX. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Adam C. Kinsey
